Systemic lupus erythematosus

Shaikh, Maliha; Jordan, Natasha; D’Cruz, David

doi:10.7861/clinmedicine.17-1-78

Cited by 48 publications

(61 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immune anomalies, particularly the production of a series of antinuclear antibodies, are another prominent feature of the disease. 1 The SLE prevalence varies from 40 to 200 cases per 100,000 inhabitants, more common among Africans and Asians descendants. In Brazil, its prevalence is around 8.7 per 100,000 inhabitants.…”

Section: General Aspectsmentioning

confidence: 99%

“…In Brazil, its prevalence is around 8.7 per 100,000 inhabitants. 1,2 The broad spectrum of clinical presentations includes mucous-cutaneous, muscle-skeletal, hematological, cardiopulmonary, renal and central nervous system manifestations. The most severe forms of organ involvement are lupus nephritis and neuropsychiatric lupus, and these conditions may result in a significant reduction in life expectancy.…”

Section: General Aspectsmentioning

confidence: 99%

“…The most severe forms of organ involvement are lupus nephritis and neuropsychiatric lupus, and these conditions may result in a significant reduction in life expectancy. 1 Lupus nephritis is one of the leading causes of death along with infections. 3 The most common general symptoms are weight loss, anemia, arthralgia and/or arthritis, being the involvement of the osteoarticular system the most frequent clinical manifestation.…”

Section: General Aspectsmentioning

confidence: 99%

“…3 The most common general symptoms are weight loss, anemia, arthralgia and/or arthritis, being the involvement of the osteoarticular system the most frequent clinical manifestation. 1 Antiphospholipid syndrome can occur in association with SLE, and it is characterized by arterial and venous thromboses, as well as recurrent morbidity in pregnancy. 4 The American College of Rheumatology (ACR) proposed the criteria for the diagnosis of SLE (►Table 1).…”

Section: General Aspectsmentioning

confidence: 99%

See 3 more Smart Citations

A Critical Review on Obstetric Follow-up of Women Affected by Systemic Lupus Erythematosus

Pastore

Costa

Parpinelli

et al. 2018

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

show abstract

Section: General Aspectsmentioning

confidence: 99%

Section: General Aspectsmentioning

confidence: 99%

Section: General Aspectsmentioning

confidence: 99%

Section: General Aspectsmentioning

confidence: 99%

See 2 more Smart Citations

A Critical Review on Obstetric Follow-up of Women Affected by Systemic Lupus Erythematosus

Pastore

Costa

Parpinelli

et al. 2018

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

show abstract

“…The course of the disease is variable and is characterized by flares of inflammation that can threaten, in an unpredictable manner, almost any organ in the body [3] . Major organ involvement may lead to significant morbidity and mortality [4] . Abnormal activation of self-reactive T and B cells, self-antibodies and immune complex production were detected in SLE [5].Although clinical assessment is the cornerstone of SLE patient management, these evaluations are limited and require additional tests to confirm diagnosis and determine disease activity.…”

Section: Introductionmentioning

confidence: 99%

Anti-Nucleosome Antibody as a Marker of Systemic Lupus Erythematosus Activity

El-Wahaab¹,

Sayed²,

Herdan³

et al. 2018

The Medical Journal of Cairo University

View full text Add to dashboard Cite

Background: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disease that is highly heterogeneous in its presentation. Effective SLE patient care relies on serological biomarkers. There is high interest in the identification of autoantibodies other than Antinuclear Antibodies (ANA) and anti-double stranded DNA (Anti-dsDNA). Aim: To evaluate the use of antinucleosome (Anti-NCS) antibody as a single marker to detect disease activity and renal involvement in SLE patients. Methods and Material: This case-control study was carried out in Clinical Pathology Department at Assiut University Hospital in the period from 2014 to 2017. It included 92 patients. Sixty-two patients were diagnosed as SLE. Thirty patients had connective tissue diseases other than SLE (non-SLE). Twenty apparently healthy subjects were taken as controls. All subjects were tested for ANA, anti-dsDNA antibody and Serum anti-NCS antibody on Alegria ® (OR-GENTEC Diagnostic GmbH-Germany). Statistical analysis: Date entry and data analysis were done using SPSS Version 19, Chicago, USA (Statistical Package for Social Science). Results: There was higher significant elevation in the level of anti-NCS antibodies than anti-dsDNA in SLE patients in comparison to those with non-SLE and control groups.In LN patients anti-NCS antibodies were highly elevated than anti-dsDNA comparing to non LN patients. Anti-NCS antibodies had a stronger correlation than anti-dsDNA antibodies with SLEDAI score. In 22 negative anti-dsDNA SLE patients, 13 (59.1%) were positive for anti-NCS. Anti-NCS antibodies showed higher sensitivity and specificity than anti-dsDNA in SLE and LN patients. Conclusion: Anti-nucleosome antibodies is highly sensitive and specific in diagnosis of SLE, especially if anti-dsDNA antibodies are absent. Anti-NCS antibodies are good disease activity markers for the assessment of SLE and LN disease activity.

show abstract

Efficacy and safety of belimumab therapy for patients with lupus nephritis: A meta‐analysis and a propensity score‐matched case–control study

Zhang

Guo

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

In this study, we performed a meta-analysis and a propensity score-matched case-control study to evaluate the efficacy and safety of belimumab in patients with lupus nephritis (LN). Methods: We analyzed the data from three randomized controlled trials (RCTs) to assess the effects of belimumab treatment on renal improvement and adverse effects. Our study included a total of six LN patients who received belimumab treatment and an additional six LN patients who received standard therapy. All participants were followed up for a duration exceeding 96 weeks to evaluate the outcomes of the treatments.Results: Our meta-analysis incorporated data from three articles involving a total of 666 patients. The results of the analysis revealed that a higher

show abstract

Systemic lupus erythematosus

Cited by 48 publications

References 32 publications

A Critical Review on Obstetric Follow-up of Women Affected by Systemic Lupus Erythematosus

A Critical Review on Obstetric Follow-up of Women Affected by Systemic Lupus Erythematosus

Anti-Nucleosome Antibody as a Marker of Systemic Lupus Erythematosus Activity

Efficacy and safety of belimumab therapy for patients with lupus nephritis: A meta‐analysis and a propensity score‐matched case–control study

Contact Info

Product

Resources

About